Enterococcus News and Research

RSS

3M introduces Clean-Trace Hygiene Management System for healthcare facilities

As part of its effort to offer a wide range of environmental hygiene solutions for healthcare facilities, 3M Infection Prevention today announced its 3M™ Clean-Trace™ Hygiene Management System. This solution is designed to help hospitals assess the cleanliness of a surface and validate the efficacy of cleaning protocols and worker performance in less than one minute

11 May 2011

Commonly used strategy has no effect in reducing MRSA, VRE in hospital ICUs

A new research study of the effect of a commonly used strategy to reduce the spread of antibiotic-resistant bacteria in hospital intensive care units shows that the strategy had no significant effect. That's the surprising finding of a multisite study led by Mayo Clinic investigators.

19 Apr 2011

Positive results from Nabriva's BC-3781 Phase II trial in ABSSSI

Nabriva Therapeutics today announced the successful results of a Phase II clinical trial of BC-3781 in acute bacterial skin and skin structure infections.

18 Apr 2011

New study: CHG cloths more effective in reducing risk of hospital-acquired infections

A new study from Rhode Island Hospital has found a reduced risk of hospital-acquired infections when using two percent chlorhexidine gluconate cloths for daily bathing instead of soap and water.

16 Feb 2011

Water contamination warnings after floods

The public has been warned to stay out of some southeast Queensland waterways containing high levels of sewage contamination from floodwaters. Moreton Bay itself has avoided major sewage contamination says the Queensland Government.

31 Jan 2011

IMDx enters multi-year agreement with Abbott Molecular for m2000 instrument system

IMDx today announced that they have signed a multi-year agreement with Abbott whereby IMDx will design, develop, regulatory clear, and manufacture assays for the Abbott Molecular FDA cleared, m2000 instrument system to be distributed worldwide. Financial terms have not been disclosed.

21 Jan 2011

Private rooms in the ICU help reduce hospital infections

A research team from the McGill University Health Centre (MUHC) and McGill University has demonstrated that private rooms in the Intensive Care Unit (ICU) play a key role in reducing hospital infections like C-difficile. The study, published today in the journal Archives of Internal Medicine, also suggests that length of stay would be shorter and this could lead to cost savings to the healthcare system.

12 Jan 2011

Cempra to present information on solithromycin antimalarial agent at Atlanta Annual Meeting

Cempra Pharmaceuticals today announced abstracts to be presented on its novel fluoroketolide antibiotic, solithromycin (CEM-101), at the American Society of Tropical Medicine and Hygiene 59th Annual Meeting, November 3 to 7 in Atlanta. The abstracts will present new information on solithromycin's antimalarial activity. Additional data will demonstrate activity against Mycobacterium leprae.

4 Nov 2010

Researchers unveil clues to combat enteritis in humans

The bacterium Campylobacter jejuni is a major cause of food poisoning in humans. It is normally transmitted from contaminted chicken meat, as it is frequently found in the intestines of chickens, where it apparently does not result in any symptoms. Researchers at the University of Veterinary Medicine, Vienna have now solved the puzzle, showing that Campylobacter can survive ambient oxygen levels thanks to the presence of other bacteria, species of Pseudomonas.

7 Oct 2010

PolyMedix presents defensin mimetic antibiotics data at ICAAC Conference

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, today presented five posters at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

16 Sep 2010

Scientists find low levels of bacteria in fields sprayed with swine manure

That swine manure sprayed on to fields adds valuable nutrients to the soil is well known. But what is not known is whether all that manure is bringing harmful bacteria with it.

13 Sep 2010

Rice receives Defense Threat Reduction Agency grant to develop genomic test for cultivated pathogens

Researchers at Rice University have won federal support to develop a genomic test that can quickly determine whether a disease outbreak is caused by a natural pathogen or one that was grown in a lab by terrorists.

17 Aug 2010

Advanced Life Sciences enters agreement with UBC to develop antimicrobial peptides

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has entered into a sponsored research and option agreement with The University of British Columbia (UBC) to develop several antimicrobial peptides.

27 Jul 2010

MRSA survivors unite across the globe to raise awareness and educate public on prevention

MRSA Survivors Network with MRSA survivors, family members and other victims of healthcare-acquired infections unite across the globe and on World MRSA Day, October 2, 2010 in a grassroots movement to raise awareness and push for more mandated reporting of infections, MRSA screening laws, funds to raise awareness and educate the public on prevention, which will save lives.

15 Jun 2010

Kansas State University researcher awarded NIH grant to study antibiotic-resistant bacteria

Antibiotic-resistant bacteria are becoming a growing problem around the world, and are a particular worry in hospital-acquired infections.

20 May 2010

Cempra Pharmaceuticals announces schedule of poster presentations at ECCMID 2010

Cempra Pharmaceuticals today announced its schedule of poster presentations at the 20th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Vienna, Austria, on April 10-13, 2010.

8 Apr 2010

Cepheid to launch GeneXpert Infinity-48 in Europe at 20th ECCMID

Cepheid will initiate European launch of its newest addition to the GeneXpert® family of molecular diagnostic testing systems, the GeneXpert Infinity-48, at the 20th annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Vienna, Austria. The GeneXpert Infinity-48 System is the world's first and only fully-automated, random-access system designed for management of the entire molecular testing workflow — from sample data, cartridge loading and unloading, to final reporting of test results and disposal of cartridges.

7 Apr 2010

Bactericidal antibiotic with activity against MRSA for treatment of cSSSIs would earn 25% patient share: Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy's effect on overall clinical success is the attribute that most influences surveyed infectious disease specialists' prescribing decisions in the treatment of complicated skin and skin structure infections (cSSSIs).

19 Mar 2010

MicuRx Pharmaceuticals files IND for MRX-I antibiotic drug candidate with Chinese SFDA

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) in China for MRX-I, its first development-stage antibiotic drug candidate. MRX-I, an orally-administered oxazolidinone, targets multi-drug resistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

15 Mar 2010

bioMerieux introduces FDA cleared chromID VRE for detecting Enterococcus faecium and Enterococcus faecalis

bioMerieux – a world leader in the field of in vitro diagnostics – today announced the launch of the first Food and Drug Administration (FDA) cleared chromID™ VRE, a simple and cost-effective solution in the struggle against vancomycin-resistant enterococci (VRE). chromID VRE is the first to receive an FDA 510(k) clearance for the qualitative detection of Enterococcus faecium and Enterococcus faecalis showing acquired resistance to vancomycin in stool specimens.

12 Mar 2010